What’s next for psychedelics after MDMA rejection?

Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.

Authors

Publication Details

Journal
Science
Published
2024-08-15
DOI
https://doi.org/10.1126/science.ads4470
Citations
9
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
5.75
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

What’s next for psychedelics after MDMA rejection?

Kai Kupferschmidt
9 citations
Science
Psychedelics and Drug Studies
5.75
article

What’s next for psychedelics after MDMA rejection?

Kai Kupferschmidt
article en
9 citations

Abstract

Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.

ScienceVol. 385(6710)
Openalex Percentile: Top 4%
Psychedelics and Drug Studies
5.75
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

What’s next for psychedelics after MDMA rejection? — Kai Kupferschmidt · Science (2024) | TGRS Research Map | TGRS